Estrella Immunopharma, Inc.(ESLA)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.0M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
ESLA Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Estrella Immunopharma, Inc. (ESLA), a Healthcare sector company. ESLA is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings (Q3 2026), Estrella Immunopharma, Inc. reports net income of $-2.3M, free cash flow of $-6.7M. Top institutional holders of ESLA by reported 13-F value include ARMISTICE CAPITAL,, VANGUARD CAPITAL MANAGEMENT, WELLS FARGO & COMPANY/MN, based on the most recent SEC filings. ESLA trades on the Nasdaq exchange and files with the SEC under CIK 1844417. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ESLA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Estrella Immunopharma, Inc. directly from SEC EDGAR.
Net Income
Q3 2026
$-2.3M
Free Cash Flow
Q3 2026
$-6.7M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Net Income
+34.2% YoYOperating Income
+34.2% YoYEPS (Diluted)
+73.3% YoYTotal Assets
+47.1% YoYOp. Cash Flow
-1102.6% YoY| Metric | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|
| Net Income | $-7.3M +34.2% | $-11.1M | — |
| Operating Income | $-7.3M +34.2% | $-11.1M | — |
| EPS (Diluted) | $-0.27 +73.3% | $-1.01 | — |
| Total Assets | $4.5M +47.1% | $3.0M -93.3% | $45.4M |
| Operating Cash Flow | $-16.1M -1102.6% | $-1.3M | — |
AI Insight: ESLA Financial Trends
Estrella remains pre-revenue with accelerating cash burn; equity has turned negative and operating losses persist across all recent quarters.
• Operating losses stabilized at $1–2M per quarter in Q4 2025 and Q1 2026, after peak $6M loss in Q2 2025.
• Operating cash flow deteriorated to −$7M in Q1 2026, worst quarter on record; cumulative burn from Q1 2025 onward exceeds $9M.
• Shareholder equity collapsed from $9M (Q4 2023) to −$5M (Q1 2026); company now technically insolvent on book value.
⚠ No revenue reported across entire period; cash runway appears limited given negative equity and ongoing quarterly burn.
⚠ Q1 2026 operating CF fell to −$7M despite modest net loss of −$2M, signaling working capital deterioration or large non-cash charges.
AI Insight: ESLA Ratio Trends
Insufficient financial data to establish meaningful trends; only one ratio (ROA of -77.2%) reported across nine periods.
• ROA deteriorated to -77.2% in Q4 2025, indicating severe profitability headwinds in the latest quarter.
⚠ Nearly all profitability and leverage metrics absent from recent quarters; data gaps prevent trend assessment.
Get alerted when ESLA's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Estrella Immunopharma, Inc. including:
Top Institutional Holders of ESLA
ARMISTICE CAPITAL, LLC
$4.3M4,099,000 shVANGUARD CAPITAL MANAGEMENT LLC
$405.4K382,469 shWELLS FARGO & COMPANY/MN
$280.3K264,388 shGEODE CAPITAL MANAGEMENT, LLC
$166.9K157,485 shVANGUARD FIDUCIARY TRUST CO
$68.8K64,921 shRENAISSANCE TECHNOLOGIES LLC
$66.6K62,795 shSTATE STREET CORP
$45.8K43,252 shBlackRock, Inc.
$42.3K39,890 shNORTHERN TRUST CORP
$20.8K19,624 shUS BANCORP \DE\
$17.9K16,904 sh
| Fund | Value | Shares |
|---|---|---|
| ARMISTICE CAPITAL, LLC | $4.3M | 4,099,000 |
| VANGUARD CAPITAL MANAGEMENT LLC | $405.4K | 382,469 |
| WELLS FARGO & COMPANY/MN | $280.3K | 264,388 |
| GEODE CAPITAL MANAGEMENT, LLC | $166.9K | 157,485 |
| VANGUARD FIDUCIARY TRUST CO | $68.8K | 64,921 |
| RENAISSANCE TECHNOLOGIES LLC | $66.6K | 62,795 |
| STATE STREET CORP | $45.8K | 43,252 |
| BlackRock, Inc. | $42.3K | 39,890 |
| NORTHERN TRUST CORP | $20.8K | 19,624 |
| US BANCORP \DE\ | $17.9K | 16,904 |
More Healthcare Companies
View all Healthcare →Put ESLA on your watchlist
Track score changes the day Estrella Immunopharma, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is ESLA a good stock to buy?
13F Pro's AI-powered analysis of Estrella Immunopharma, Inc. (ESLA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ESLA are available on the ESLA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own ESLA?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ESLA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Estrella Immunopharma, Inc.'s investment landscape.